ibrutinib for Lymphoma
This study is evaluating whether a drug called ibrutinib can be given to patients with mantle cell lymphoma (MCL) as maintenance therapy after induction chemotherapy.
See full descriptionAbout the trial for Lymphoma
Treatment Groups
This trial involves 2 different treatments. Ibrutinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether ibrutinib will improve 1 primary outcome, 3 secondary outcomes, and 1 other outcome in patients with Lymphoma. Measurement will happen over the course of Four time-points: baseline (pre-treatment), after 1 month and 6 months of treatment, and approximately 18-24 months post-first dose of treatment.
Patient Q & A Section
What causes lymphoma?
The most common form of lymphoma is diffuse large B-cell lymphoma, which may be related to an environmental exposure such as exposure to cigarette smoke. This is because cigarette smoking increases the risk of developing other types of lymphoma. The risk of developing lymphoma rises with the number of cigarettes smoked and with increasing age, especially for stomach/intestinal-type lymphoma.
How many people get lymphoma a year in the United States?
The American Cancer Society estimates that 30,600 cases of Hodgkin disease and 18,400 cases of non-Hodgkin's lymphoma will be diagnosed in the United States in 2017. The most common form of lymphoma is diffuse large B cell lymphoma. Other forms of NHL include anaplastic large cell lymphoma and mantle cell lymphoma.\n
Can lymphoma be cured?
The most common (and curable) form of lymphoma is diffuse large B-cell lymphoma (50%), which tends to have better outcomes than most other lymphomas, as measured by the five-year relative survival rate (65% relative survival, compared to less than 20% for Burkitt's and Burkitt-like lymphomas). The prognosis for follicular lymphoma is poor. The remaining lymphomas are more difficult to treat, but some of these - particularly non-Hodgkin's lymphomas and (somewhat more) poor prognosis non-Hodgkin's lymphomas - can be cured, and long-term survivals have been achievable.
What are common treatments for lymphoma?
Treatments may be varied depending on severity, stage of disease, and comorbidity. When possible, chemotherapy is normally the treatment of choice for early stage disease. It can be combined with radiotherapy to increase the overall effectiveness and control of the disease. As chemotherapy and radiation are effective for most cases of lymphoma, most treatments are tailored towards each case's individual needs. Radiation is often used when patients present with recurrent disease to address symptoms or minimize recurrence, including local symptoms from a second tumour. Lymphomas are radiosensitive and may respond to radiation and chemotherapy to a satisfactory degree.
What are the signs of lymphoma?
There is a wide variety in the signs of peripheral Non-Hodgkin’s lymphoma and non-malignant disorders. However, the combination of symptoms can help diagnose the exact pathology.
What is lymphoma?
Although lymphoma is also an orphan disease it was not a part of this study. Most of the patients were older males, the median age of diagnosis was 73 years. Lymphoma was associated with a variety of clinical features, many of which were age related.
How quickly does lymphoma spread?
In our series, the most frequent sites for lymphoma metastases were lungs and liver, whereas other parts of the body are only rarely involved. We also found that lymphoma seems to diffuse from site to site more slowly than reported in other studies. Lymphoma seems to spread more slowly than, but similar as, most other malignancies if there are no clinical signs of a very high lymphoma burden.
What is the average age someone gets lymphoma?
Most lymphomas are detected in people aged 60 to 69 years, even though most lymphomas occur in adults, and younger people get a much higher proportion of T- and B-cell lymphomas. The most common lymphoma is follicular lymphoma. The mean age at diagnosis is 63 years for cutaneous T-cell lymphomas. It is imperative that lymphoid diseases in the elderly are recognized early to ensure that good-enough treatment is offered and that they receive it early enough to increase their chances of survival to their full potential.
Who should consider clinical trials for lymphoma?
The vast majority of trial-eligible patients die before the completion of a trial, so the data from those patients have little bearing in decisions about treatment in the community. The study does give some useful insights into patient characteristics. Results from a recent clinical trial of clinical trials are generally more relevant to care in the community than to patient characteristics. If all the available data were pooled, the study would show similar patterns when considering many of the other treatments available in Canada at the time of the database’s completion. Most clinical trials were not designed to evaluate patient characteristics; therefore, the results of the Loyola Study of the 1980s are interesting because data from that study do not show differences in survival among subtypes with respect to specific patient characteristics.
Have there been other clinical trials involving ibrutinib?
Recent findings of this trial add to the body of evidence supporting the activity of ibrutinib in patients with relapsed or refractory rituximab- or bortezomib-resistant mantle cell Lymphoma and warrants further clinical investigation of ibrutinib for treatment of ibrutinib-refractory disease.
How serious can lymphoma be?
It is important in determining prognosis and future therapeutic decisions for patients with aggressive lymphoma that we possess the following criteria: A. A score of > 10 on the Memorial Sloan-Kettering Cancer Institute's pre-treatment Lymphoma Staging Score on a 10 point scale based on Burden of disease: Presence or absence of extranodal tissue involvement; presence of visceral/vascular involvement and/or organ involvement; presence of distant involvement or bone marrow involvement\nB. Presence of advanced disease and/or symptomatic cancer-related symptoms; B.
Does lymphoma run in families?
It is clear that lymphoma runs in families as shown by the recurrences over several generations. The exact cause(s) is unknown, but this knowledge may provide a basis for understanding the risk factors that may influence prevention of lymphoma, and may help to refine the use of chemotherapy. The fact that only one of the families with 2 confirmed cases occurred in an ethnic group with higher than normal incidence should prompt one to look at genetic variants which might predispose to this specific type of lymphoma. The implication is that other ethnic groups may have a distinct genetic profile in terms of lymphoma risk, and that genetic variants associated with lymphoma risk would be identifiable. This information might assist in risk-adaptation.